KEYNOTE-775: Updates from SGO 2023

EP: 1.Overview of Endometrial Carcinoma

EP: 2.Molecular Profiling and Risk Stratification in Advanced Endometrial Carcinoma

EP: 3.Standard Treatments for Patients with Advanced Endometrial Carcinoma

Now Viewing

EP: 4.KEYNOTE-775: Updates from SGO 2023

EP: 5.Patient Tolerability with Lenvatinib plus Pembrolizumab

EP: 6.Additional Highlights from SGO 2023

EP: 7.Future Directions in Advanced Endometrial Carcinoma

Transcript:

David O’Malley, MD: [The] KEYNOTE-775 [trial] [NCT03517449]…was lenvatinib-pembrolizumab vs standard-of-care chemotherapy, [which] included weekly paclitaxel or doxorubicin. We had a marked improvement in the patients who received lenvatinib-pembrolizumab, with a median progression-free survival in the proficient patients of 6.6 vs 3.8 months, [which] was the primary analysis.

We actually saw an improvement in overall survival by 5.5 months, 17.4 vs 12 months. We actually saw an improvement in the median overall survival in the lenvatinib-pembrolizumab arm. In the proficient population, you’ve seen an improvement of 7 [months], to 17.4 months vs 12 months in the chemotherapy. In the overall population, you saw a 7-month improvement, from 18.3 vs 11.4 months.

Dr Vicky Makker presented KEYNOTE-775, which was pembrolizumab-lenvatinib vs physician-choice chemotherapy in patients who had previously been treated with systemic chemotherapy. In the all-comers population, the overall response rate was actually 34%. When we look at the group of patients with MMR [mismatch repair] proficient disease, the overall response rate was 32.4%. Actually, almost 6% of patients had a complete response. As we look at the outcomes between these patients, you have a marked improvement in the lenvatinib-pembrolizumab arm as compared to chemotherapy.

Transcript edited for clarity.